Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM AHCT for HIV-associated Lymphoma
NCT01141712Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Apr 2010
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine, etoposide, cytarabine and melphalan in diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), sponsored by Medical College of Wisconsin. Primary endpoint: Overall Survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
carmustineetoposidecytarabinemelphalan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01141712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141712.